肿瘤学与转化医学（英文）2025，Vol.11Issue(4)：195-197,3.DOI:10.1097/ot9.0000000000000089
Exceptional and durable response with pembrolizumab in a patient with microsatellite stable metastatic castrate-resistant prostate cancer:High tumor mutational burden and circulating tumor DNA clearance as predictive biomarkers
Exceptional and durable response with pembrolizumab in a patient with microsatellite stable metastatic castrate-resistant prostate cancer:High tumor mutational burden and circulating tumor DNA clearance as predictive biomarkers
Cherry Au 1Changtai Tian 1Revathi Kollipara 2David Vanderweele 3Trevor Christ 4Andrew Kelly 5Alan Tan6
作者信息
- 1. Department of Internal Medicine,Rush University Medical Center,Chicago,IL
- 2. Division of Hematology,Oncology,and Cellular Therapies,Rush University Medical Center,Chicago,IL
- 3. Division of Hematology/Oncology,Northwestern University,Chicago,IL
- 4. Department of Pharmacy,Rush University Medical Center,Chicago,IL
- 5. Foundation Medicine,Cambridge,MA
- 6. Division of Hematology/Oncology,Vanderbilt University Medical Center,Nashville,TN
- 折叠
摘要
关键词
ctDNA/Precision medicine/Prostate cancer/TMBKey words
ctDNA/Precision medicine/Prostate cancer/TMB引用本文复制引用
Cherry Au,Changtai Tian,Revathi Kollipara,David Vanderweele,Trevor Christ,Andrew Kelly,Alan Tan..Exceptional and durable response with pembrolizumab in a patient with microsatellite stable metastatic castrate-resistant prostate cancer:High tumor mutational burden and circulating tumor DNA clearance as predictive biomarkers[J].肿瘤学与转化医学（英文）,2025,11(4):195-197,3.
